Mp15-17 retzius-sparing robot assisted radical prostatectomy has similar 1-year functional and oncological outcomes as standard robot-assisted radical prostatectomy: results from a high volume uk centre

You have accessJournal of UrologyCME1 May 2022MP15-17 RETZIUS-SPARING ROBOT ASSISTED RADICAL PROSTATECTOMY HAS SIMILAR 1-YEAR FUNCTIONAL AND ONCOLOGICAL OUTCOMES AS STANDARD ROBOT-ASSISTED RADICAL PROSTATECTOMY: RESULTS FROM A HIGH VOLUME UK CENTRE Paolo Umari, Tushar Aditya Narain, Dominic Eden, Declan Cahill, Christopher Eden, and Prasanna Sooriakumaran Paolo UmariPaolo Umari More articles by this author , Tushar Aditya NarainTushar Aditya Narain More articles by this author , Dominic EdenDominic Eden More articles by this author , Declan CahillDeclan Cahill More articles by this author , Christopher EdenChristopher Eden More articles by this author , and Prasanna SooriakumaranPrasanna Sooriakumaran More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002544.17AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Retzius-Sparing Robot-Assisted Radical Prostatectomy (RS-RARP) has been shown to have better immediate functional outcomes (urinary continence and erectile function) as compared to Standard Robot-Assisted Radical Prostatectomy (S-RARP). We evaluated the 1-year oncological and functional outcomes in patients undergoing RS- RARP as compared to S-RARP using prospectively collected patient-reported outcome measures (PROMs) and Quality of Life (QoL) scores. METHODS: Patient and physician-reported data for 551 patients who underwent RS-RARP and S-RARP from August 2017 to November 2020 by three experienced robotic surgeons were prospectively collected. Perioperative and pentafecta outcomes were analyzed using SPSS software. PROMs for erectile function, urinary continence and QoL were recorded at baseline and at 7 days, and 1,3,6,9 and 12 months postoperatively. RESULTS: 291 patients underwent S-RARP and 260 patients underwent RS-RARP. Patient and tumor characteristics were broadly similar in both groups. Rates of positive surgical margins (p=0.080) and biochemical recurrence at 1-year were similar in both the groups (p=0.117). The PROMs reported outcomes for erectile function recovery (p=0.57), urinary function including continence recovery (p=0.151) and QoL (p=0.82) at 12 months were also similar between the two groups. CONCLUSIONS: RS-RARP has similar long term oncological and functional outcomes, and therefore should only be offered to selected patients in whom confidence is high regarding oncological outcomes. Men at high risk of early post- operative incontinence (age>70, BMI>30, MUL<14mm) with low risk of positive surgical margins (posteriorly located tumours) are good candidates for RS-RARP. Source of Funding: none © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e248 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Paolo Umari More articles by this author Tushar Aditya Narain More articles by this author Dominic Eden More articles by this author Declan Cahill More articles by this author Christopher Eden More articles by this author Prasanna Sooriakumaran More articles by this author Expand All Advertisement PDF downloadLoading ...